Cumulative Irritation Potential and Contact Sensitization Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch Studies
Overview
Affiliations
We performed 2 phase 1 patch studies to evaluate tazarotene foam 0.1% for cumulative irritation potential (study A) and contact sensitization potential (study B). Study A participants wore patches containing active study product, vehicle foam, and positive and negative controls for 24 +/- 1 hours for 21 consecutive days. Irritation scores were statistically higher with tazarotene foam 0.1% than vehicle foam and both controls. Fourteen participants (36%) experienced product-related, application-site adverse events (AEs); all of the AEs were mild and transient. Study B participants were exposed to active product and vehicle foam for an induction and challenge phase. At the investigators discretion, participants were administered a rechallenge to evaluate for contact sensitization. Three participants demonstrated questionable sensitization reactions and underwent a rechallenge; none of the participants displayed conclusive contact sensitization. Three application-site AEs were considered to be product related; none of the AEs led to study discontinuation. Tazarotene foam 0.1% showed potential to induce irritation but a low potential for contact sensitization and an acceptable tolerability and safety profile.
Del Rosso J, Kircik L, Lin T, Pillai R J Clin Aesthet Dermatol. 2019; 12(1):11-15.
PMID: 30881571 PMC: 6405249.
Use of tazarotene foam for the treatment of acne vulgaris.
Gregoriou S, Kritsotaki E, Katoulis A, Rigopoulos D Clin Cosmet Investig Dermatol. 2014; 7:165-70.
PMID: 24920932 PMC: 4043801. DOI: 10.2147/CCID.S37327.
Contact sensitizing potential of pyrogallol and 5-amino-o-cresol in female BALB/c mice.
Guo T, Germolec D, Zhang L, Auttachoat W, Smith M, White Jr K Toxicology. 2013; 314(2-3):202-8.
PMID: 24172597 PMC: 3862031. DOI: 10.1016/j.tox.2013.10.006.
Safety and efficacy of tazarotene foam for the treatment of acne vulgaris.
Epstein E, Gold L Clin Cosmet Investig Dermatol. 2013; 6:123-5.
PMID: 23696711 PMC: 3658431. DOI: 10.2147/CCID.S34054.